Effectiveness of treatments for metastatic uveal melanoma.
about
Development and external validation of a prognostic nomogram for metastatic uveal melanomaMetastatic disease from uveal melanoma: treatment options and future prospectsAnimal Models of Uveal Melanoma: Methods, Applicability, and LimitationsUpcoming translational challenges for uveal melanomaMicroRNA dysregulation in uveal melanoma: a new player enters the gameTargeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenograftsPhase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanomaStudy design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).Expression analysis of genes and pathways associated with liver metastases of the uveal melanoma.Atypical Presentation: Metastatic Uveal Melanoma in a Young Patient without Visual Complaints.A molecular revolution in uveal melanoma: implications for patient care and targeted therapyGenetic evolution of uveal melanoma guides the development of an inflammatory microenvironment.Uveal melanoma cell growth is inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase.A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature.Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma: Clinical Outcomes and the Predictive Value of Fluorodeoxyglucose Positron Emission Tomography.Does ocular treatment of uveal melanoma influence survival?The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.The genetics of uveal melanoma: an emerging framework for targeted therapyPhase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.The DecisionDx-UM Gene Expression Profile Test Provides Risk Stratification and Individualized Patient Care in Uveal MelanomaOverexpression of high mobility group A1 protein in human uveal melanomas: implication for prognosis.Progression of ocular melanoma metastasis to the liver: the 2012 Zimmerman lecture.Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapyCollaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanomaHigh levels of Hdmx promote cell growth in a subset of uveal melanomas.Nonlethal Levels of Zeaxanthin Inhibit Cell Migration, Invasion, and Secretion of MMP-2 via NF-κB Pathway in Cultured Human Uveal Melanoma CellsClass III-specific HDAC inhibitor Tenovin-6 induces apoptosis, suppresses migration and eliminates cancer stem cells in uveal melanomaPhase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma.Checkpoint modulation in melanoma: an update on ipilimumab and future directions.Zeaxanthin Induces Apoptosis in Human Uveal Melanoma Cells through Bcl-2 Family Proteins and Intrinsic Apoptosis Pathway.Subtoxic Levels of Apigenin Inhibit Expression and Secretion of VEGF by Uveal Melanoma Cells via Suppression of ERK1/2 and PI3K/Akt Pathways.Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma.Systemic treatment of metastatic uveal melanoma: review of literature and future perspectivesCirculating tumor cells in uveal melanoma.The pathology of ocular cancer.Trametinib (GSK1120212) in the treatment of melanoma.Implication of ultraviolet light in the etiology of uveal melanoma: A review.Patient-derived xenografts recapitulate molecular features of human uveal melanomas.Clinical and histopathological features and immunoreactivity of human choroidal and ciliary melanomas as prognostic factors for metastasis and death.
P2860
Q21131800-D52E412B-FEFF-4FC4-A784-8CF7CE06EDA2Q26738377-8BAFD893-A971-434F-8B5D-21C2A433897BQ26745595-3BB5475E-3242-4E20-B6CB-30D25C763FD7Q26778535-43BEAC72-9AC4-4B54-BC02-0A8E5099BE5DQ27026746-718F990B-2398-4B58-90BC-98B34184A910Q28538631-2C10C734-55A1-4007-B912-91EB350520EDQ28543960-7A47A518-FC92-4CEA-9996-090173D035ECQ30384829-4D23B236-61EA-4166-B079-086578E6F02DQ33589266-B695F8C2-3898-488B-B3C5-C25081E7A611Q33701061-AA8CABAF-5B3A-44BA-9430-A399FBAA0B9AQ33717375-0AF775F1-AA83-4E58-89BC-794E7FA8DB8EQ33849590-8F547686-035B-48D1-B832-D5EA485280F2Q33872396-F767144A-AA17-4FB7-8F1A-A8246BDE20EBQ33885560-A6355F70-0877-41E6-9F16-F2FD97CC006DQ33911553-197612F5-33E2-40FF-B2EC-92FCBB459E6DQ34059687-9C871DA4-13F0-4BCF-819E-3D8B299A1268Q34096861-65141EC1-958A-4D42-95EF-7CBD69127AF3Q34249080-9C3767B5-94AD-44AF-9237-7EBC78BBED1FQ34504963-ECA493C4-BF3A-4FFB-89CA-BA706411E679Q34660509-744A2A5C-01C8-4DB1-9D11-96374E3E5BC7Q34671160-9D7FEAAC-F4B1-42CC-9BC0-4DCE5FBDD45BQ34918493-07B49708-D3EF-4EBF-BD6F-07998766F4C0Q35755594-349D4A50-1CAE-4B6B-8E3D-D032917A2A9CQ36107158-3484DD9E-C3A2-4740-8DBB-66566D92BFE2Q36113448-0FCCECF0-25D7-47C1-A1AB-AD6C3B9D68D8Q36206473-BB3DDF4B-0945-44E3-9868-8FE4B366B459Q36569013-2BF3FA1C-365D-4056-8983-196564EB8003Q36651002-A26D2FA3-C23C-4DC8-91B1-0B2E1CB44B02Q36673510-7A0FC56A-F9F4-412F-8AAC-56D0F1749E39Q37237761-F4535611-E0E7-4889-A6E1-B73D99068683Q37261208-7210E480-B97C-4819-98FC-2959FB61F95EQ37322759-4303F29A-5365-4A03-903B-1720F32C7009Q37381602-89F5D54C-F579-47D7-8172-2AFD811E2B29Q37482566-A4F1CE37-DF3B-4686-8FE5-73EFE8ADF679Q37822739-413C5E9F-09E6-4600-A517-DA004F950EC0Q38060067-F99E02AB-5500-4E2C-9E32-CC5CD27DB912Q38083794-73F51C9B-40F5-4149-825B-C1E4393CE82CQ38131837-C2954183-2ED9-4E79-AB07-A2510D4FD413Q38317188-D40B618C-1449-45E4-B073-296489E33760Q38408784-43BED960-CC18-4395-9425-E52E64C473BE
P2860
Effectiveness of treatments for metastatic uveal melanoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effectiveness of treatments for metastatic uveal melanoma.
@en
Effectiveness of treatments for metastatic uveal melanoma.
@nl
type
label
Effectiveness of treatments for metastatic uveal melanoma.
@en
Effectiveness of treatments for metastatic uveal melanoma.
@nl
prefLabel
Effectiveness of treatments for metastatic uveal melanoma.
@en
Effectiveness of treatments for metastatic uveal melanoma.
@nl
P1476
Effectiveness of treatments for metastatic uveal melanoma
@en
P2093
Adeel H Shaikh
James J Augsburger
P304
P356
10.1016/J.AJO.2009.01.023
P407
P577
2009-04-17T00:00:00Z